EGFR and metastatic malignant neoplasm in the lymph nodes: The recent Korean study found that ctDNA detection was associated with poorer PFS in patients treated with EGFR TKIs, and also identified ctDNA detection and extrathoracic lymph node metastasis as independent factors predicting poorer PFS [39].